Annual Meeting 2014: Dose-dependent efficacy of DARA as monotherapy in patients with relapsed or refractory MM

Annual Meeting 2014: Dose-dependent efficacy of DARA as monotherapy in patients with relapsed or refractory MM

384 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Henk Lokhorst, MD University Medical Center Utrecht Utrecht, the Netherlands Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM) Pts with RR MM received DARA for 9 wks in doses of 0.005-24mg/kg in the GEN501 dose-escalation part (Lokhorst: EHA 2013 abstract S576). The purpose of the GEN501 expansion part, which has completed enrollment, was to evaluate safety and efficacy of 2 doses of DARA for up to 24 mths using alternate dose schedules Visit our website at: http://www.myeloma.org
Up Next Autoplay